ライフサイエンスコーパス: premenstrual

1 ing 2 menstrual cycle phases (periovulatory, premenstrual).

2 5-HTT BP(ND) (periovulatory = 1.65 [0.24] > premenstrual = 1.49 [0.41], delta = -0.17 [0.33]: t(28)

3 (ND) (mean [SD] periovulatory = 1.64 [0.40], premenstrual = 1.93 [0.40], delta = 0.29 [0.47]: t(29) =

4 pment and initial validation of the Carolina Premenstrual Assessment Scoring System (C-PASS).

5 hases (Menses, Follicular, Early-Luteal, and Premenstrual) based on self-reported start date of most

6 than the placebo group as assessed by total premenstrual Daily Symptom Rating Form scores for 3 trea

7 for the association between the presence of premenstrual disorder symptoms and the PRSs for major ps

8 Premenstrual disorder symptoms were present in 12 316 of

9 Premenstrual disorders (PMDs) adversely affect the quali

10 Premenstrual disorders (PMDs) and perinatal depression (

11 Although premenstrual disorders (PMDs) end at menopause, it is un

12 ng data suggest that more than two-thirds of premenstrual disorders (PMDs), including premenstrual sy

13 Premenstrual disorders (PMDs), including premenstrual sy

14 Premenstrual disorders are heritable, clinically heterog

15 s of premenstrual disorders, indicating that premenstrual disorders have overlapping genetic foundati

16 The symptoms of premenstrual disorders were assessed at recruitment at w

17 The symptoms of premenstrual disorders were associated with the PRSs for

18 ic disorders was associated with symptoms of premenstrual disorders, indicating that premenstrual dis

19 isorder were associated with the symptoms of premenstrual disorders, using the PRS for height as a so

20 ic disorders are associated with symptoms of premenstrual disorders.

21 Premenstrual dosing does not differ from continuous dosi

22 has been linked to the use of this drug for premenstrual dsyphoria.

23 % of the nondepressed women met criteria for premenstrual dysphoria (symptom cyclicity and at least m

24 The role of ovarian steroids in both premenstrual dysphoria and perimenopausal depression has

25 icantly better than placebo for treatment of premenstrual dysphoria as reflected by symptomatic impro

26 neither menses-related symptom cyclicity nor premenstrual dysphoria was an invariant accompaniment of

27 Additionally, the rate of premenstrual dysphoria was not predicted by initial self

28 rate of menses-related symptom cyclicity and premenstrual dysphoria was observed in perimenopausal de

29 re useful therapeutic options for women with premenstrual dysphoria.

30 Premenstrual dysphoric disorder (PMDD) affects over 5% o

31 id metabolite allopregnanolone in women with premenstrual dysphoric disorder (PMDD) and in asymptomat

32 strual cycle in healthy women and those with premenstrual dysphoric disorder (PMDD) and that a menstr

33 Despite evidence for the validity of premenstrual dysphoric disorder (PMDD) and the inclusion

34 Premenstrual dysphoric disorder (PMDD) disrupts the live

35 ymptoms repeatedly experienced by women with Premenstrual Dysphoric Disorder (PMDD) during the late l

36 There is substantial information that premenstrual dysphoric disorder (PMDD) is a clinically s

37 Premenstrual dysphoric disorder (PMDD) is a common mood

38 Premenstrual Dysphoric Disorder (PMDD) is characterized

39 Premenstrual dysphoric disorder (PMDD) is characterized

40 other psychiatric illnesses tested, although premenstrual dysphoric disorder (PMDD) may be an excepti

41 ors previously demonstrated that symptoms of premenstrual dysphoric disorder (PMDD) remit during ovar

42 Premenstrual dysphoric disorder (PMDD) symptoms are elim

43 bitors (SRIs) are efficacious treatments for premenstrual dysphoric disorder (PMDD) when given daily

44 uggests that mood and behavioral symptoms in premenstrual dysphoric disorder (PMDD), a common, recent

45 ), including premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD), are associated w

46 of multiple psychiatric disorders, including premenstrual dysphoric disorder (PMDD).

47 ontext of underrecognized conditions such as Premenstrual Dysphoric Disorder (PMDD).

48 rual cycle are distinguishable in women with premenstrual dysphoric disorder (PMDD).

49 ; most of these women also meet criteria for premenstrual dysphoric disorder (PMDD).

50 h catamenial epilepsy and enhance anxiety in premenstrual dysphoric disorder (PMDD).

51 Patients with premenstrual dysphoric disorder (whose symptoms had remi

52 acebo-controlled protocol to nine women with premenstrual dysphoric disorder and 11 healthy female vo

53 a GABA levels were measured in 27 women with premenstrual dysphoric disorder and 21 comparison women

54 Women with premenstrual dysphoric disorder and a past history of ma

55 ssociations were particularly pronounced for premenstrual dysphoric disorder and for PMDs with sympto

56 order, 21 with major depression, and 10 with premenstrual dysphoric disorder and in 34 normal compari

57 roup of experts to examine the literature on premenstrual dysphoric disorder and provide recommendati

58 equested participation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200

59 tal ill health, including menstruation (with premenstrual dysphoric disorder appearing for the first

60 Premenstrual dysphoric disorder appears to be associated

61 tients with panic disorder and patients with premenstrual dysphoric disorder are highly susceptible t

62 In women with premenstrual dysphoric disorder but no past major depres

63 the hypothesis of serotonergic deficiency in premenstrual dysphoric disorder by measuring the prolact

64 The patients with premenstrual dysphoric disorder experienced a return of

65 pared to the normal subjects, the women with premenstrual dysphoric disorder had a significantly blun

66 e whether efficacy for premenstrual syndrome/premenstrual dysphoric disorder is a general or more ser

67 Premenstrual dysphoric disorder is an important cause of

68 Premenstrual dysphoric disorder is often associated with

69 e disorder and a state-dependent decrease in premenstrual dysphoric disorder might imply a possible c

70 The panic rate for patients with premenstrual dysphoric disorder was similar to that for

71 thors sought to determine whether women with premenstrual dysphoric disorder with or without prior ma

72 depression, anxiety, postpartum depression, premenstrual dysphoric disorder, and schizophrenia and (

73 nic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and social phobia.

74 (PMDs), including premenstrual syndrome and premenstrual dysphoric disorder, have symptom onset duri

75 ents with major depression and patients with premenstrual dysphoric disorder, respectively).

76 relation to the menstrual cycle, as in DSM-5 premenstrual dysphoric disorder, symptom changes of simi

77 Premenstrual dysphoric disorder, which affects 2%-5% of

78 ction may be involved in the pathogenesis of premenstrual dysphoric disorder.

79 rual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder.

80 disorders, such as postpartum depression and premenstrual dysphoric disorder.

81 ission in the efficacy of SSRI treatment for premenstrual dysphoric disorder.

82 in reuptake inhibitors (SSRIs) in women with premenstrual dysphoric disorder.

83 fective for severe premenstrual syndrome and premenstrual dysphoric disorder.

84 ical link between subtypes of depressive and premenstrual dysphoric disorders.

85 women recruited for retrospectively reported premenstrual emotional symptoms provided two to four mon

86 women recruited for retrospectively reported premenstrual emotional symptoms provided two to four mon

87 o relapse was compared between 66 women with premenstrual exacerbation (51.2%) and 63 without.

88 episodes was compared between 191 women with premenstrual exacerbation (65.2%) and 102 women without.

89 Women with premenstrual exacerbation had a shorter time to relapse

90 Women with premenstrual exacerbation had more depressive and mood e

91 During follow-up, the group with premenstrual exacerbation had more episodes (primarily d

92 Women with bipolar disorder and premenstrual exacerbation have a worse course of illness

93 Premenstrual exacerbation may be a clinical marker predi

94 isorder in prospectively followed women with premenstrual exacerbation.

95 h a validated scale based on the Calendar of Premenstrual Experiences.

96 Premenstrual mood symptoms were evaluated in women with

97 resonance imaging in female subjects without premenstrual mood symptoms, we found that OFC activity t

98 extracellular serotonin loss underlying the premenstrual onset of depressed mood in patients with PM

99 first 3 days of menses rather than only the premenstrual phase.

100 nses phase when compared to Early-Luteal and Premenstrual phases.

101 ession in some women, as observed during the premenstrual, postpartum, and perimenopausal phases, and

102 Retrospectively reported premenstrual-related symptoms of depression and anxiety

103 Lifetime major depression and premenstrual-related tiredness, sadness, and irritabilit

104 A single premenstrual symptom factor was found that was moderatel

105 previous evidence, retrospective reports of premenstrual symptom increases were a poor predictor of

106 was defined as a decrease of at least 50% in premenstrual symptom score from the pretreatment baselin

107 t during the follicular phase and related to premenstrual symptom severity.

108 rogesterone-derived neuroactive steroids and premenstrual symptom severity.

109 a mild decrease later did not report higher premenstrual symptoms (beta = 0.06; 95% CI, 0.00-0.12).

110 ore; 95% CI, 1.03-1.15) and higher burden of premenstrual symptoms (beta = 0.06; 95% CI, 0.04-0.08).

111 hroughout adolescence had a higher burden of premenstrual symptoms (beta = 0.17; 95% CI, 0.08-0.27) c

112 In 2013, premenstrual symptoms and identified PMDs were assessed

113 tic and environmental risk factors for these premenstrual symptoms and lifetime major depression are

114 elationship of the familial risk factors for premenstrual symptoms and major depression.

115 tudies suggest that retrospectively reported premenstrual symptoms are heritable, these studies have

116 the heritability of the stable component of premenstrual symptoms at 56% and showed no impact of fam

117 d body size was associated with PMD risk and premenstrual symptoms in young adulthood.

118 nd none of the comparison subjects described premenstrual symptoms on self-reports.

119 PMDs were ascertained using a modified Premenstrual Symptoms Screening Tool, supplemented by di

120 atment during the interval from the onset of premenstrual symptoms through the first few days of mens

121 he associations of BMI for age with PMDs and premenstrual symptoms were examined using log-binomial a

122 However, 5 of 8 premenstrual symptoms were significantly associated with

123 formation on recent menstrual regularity and premenstrual symptoms, as well as on sociodemographic, s

124 not active smoking, higher body mass index, premenstrual symptoms, perceived stress, and age were al

125 dividual hormone sensitivity as estimated by premenstrual symptoms.

126 iagnoses and confirmed absence of or minimal premenstrual symptoms.

127 ed and 9% of the nondepressed women reported premenstrual symptoms.

128 status, cigarette smoking, nulliparity, and premenstrual symptoms.

129 Women without premenstrual syndrome (normal women) participated in a s

130 Clinically significant premenstrual syndrome (PMS) affects 15-20% of premenopau

131 Moderate to severe premenstrual syndrome (PMS) affects as many as 20% of pr

132 Premenstrual disorders (PMDs), including premenstrual syndrome (PMS) and premenstrual dysphoric d

133 (4) and delta subunits, using a rat model of premenstrual syndrome (PMS) in which 1-3 mM alcohol pref

134 her minerals might impact the development of premenstrual syndrome (PMS) through multiple mechanisms,

135 onses to placebo medication of patients with premenstrual syndrome (PMS) who were randomly assigned i

136 rlying hypertension might also contribute to premenstrual syndrome (PMS), but whether women with PMS

137 Symptoms of premenstrual syndrome (PMS), such as anxiety and seizure

138 cle to cycle symptom stability in women with premenstrual syndrome (PMS).

139 tentially involved in the pathophysiology of premenstrual syndrome (PMS).

140 being used as first-line therapy for severe premenstrual syndrome (PMS).

141 About 5-8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also me

142 onin reuptake inhibitor in women with severe premenstrual syndrome and determined the effects of post

143 ogenous 3alpha,5alpha-THP withdrawal such as premenstrual syndrome and postpartum or postmenopausal d

144 of premenstrual disorders (PMDs), including premenstrual syndrome and premenstrual dysphoric disorde

145 reuptake inhibitors are effective for severe premenstrual syndrome and premenstrual dysphoric disorde

146 The symptoms of women with premenstrual syndrome improve in response to suppression

147 ausal treatment to vasomotor symptoms, or to premenstrual syndrome in premenopausal women, neglects a

148 er from continuous dosing with sertraline in premenstrual syndrome treatment.

149 The 10 women with premenstrual syndrome who were given leuprolide had a si

150 The 10 women with premenstrual syndrome who were given leuprolide plus est

151 received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone dur

152 menopausal women, alleviate the symptoms of premenstrual syndrome, and reduce persistent urinary tra

153 ate 40 species were used for the symptoms of premenstrual syndrome, heavy menstrual bleeding, and dys

154 fter adjusting for smoking, body mass index, premenstrual syndrome, hot flashes, poor sleep, health s

155 ion, including history of depression, severe premenstrual syndrome, poor sleep, age, race, and employ

156 roids have been implicated in the genesis of premenstrual syndrome, postpartum depression, and other

157 In women with premenstrual syndrome, the occurrence of symptoms repres

158 effects of B vitamins in the development of premenstrual syndrome.

159 tory response is unknown in the treatment of premenstrual syndrome.

160 and are important to define in treatment of premenstrual syndrome.

161 and was well tolerated by women with severe premenstrual syndrome.

162 or placebo on symptoms in 20 women with the premenstrual syndrome.

163 contributed only modestly to the etiology of premenstrual syndrome.

164 depressant to determine whether efficacy for premenstrual syndrome/premenstrual dysphoric disorder is

165 Primary outcome measures were the Rating for Premenstrual Tension observer and self-ratings completed

166 Premenstrual Tension Scale (PMTS) score was the primary

167 Finally, the Rating for Premenstrual Tension scores in the second and third estr

168 and observer-rated scores on the Rating for Premenstrual Tension were significantly increased (more

169 The primary outcome was the change in premenstrual total score on the Daily Record of Severity

170 were noted in prevalence or colony counts at premenstrual versus mid- and postmenstrual visits for mo

171 four measured negative mood symptoms in the premenstrual versus the postmenstrual week); 5 of these

172 gnificantly different between tampons at the premenstrual visit, when unusually low values were obser